Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer

Summary

This phase II trial is studying how well giving sorafenib with interferon alfa works in treating patients with metastatic or unresectable kidney cancer. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Interferon alfa may interfere with the growth of tumor cells and slow the growth of kidney cancer. Sorafenib may help interferon alfa work better by making tumor cells more sensitive to the drug

Timeline

Start

2004-09

Primary completion

2006-05

Completion

—

Drugs

Indications